Nitrosamine Impurities Affecting Drug-Drug Interaction Studies – Learn More

Biopharmaceutical Industry Recognizes Celerion as a Leading Contract Research Organization

(Lincoln, NE April 3, 2018) – For the third consecutive year, biopharmaceutical industry executives have selected Celerion as an industry leader in multiple categories of Life Science Leader’s annual CRO Leadership Awards for 2018.

Celerion was recognized as a CRO Leader in the  Capabilities, Compatibility, Expertise, Quality and Reliability categories across all three groups of respondents (big pharma, small pharma, and overall (combined big and small pharma).

“We recognize that our clients are faced with increasing complexities and challenges in drug development as well as choices in development partners. We thank them for this recognition and for their continued trust in our dedication to providing them with high-quality work. It is through their support that we are able to advance our mission of helping them get their drugs to market faster, so that together, we touch the lives of our family, friends and people in need around the world,” said Susan Thornton, President and CEO.

The survey queried the direct client experience across 27 different performance metrics spanning technical expertise to client service; results have been published in the May edition of Life Science Leader magazine.

Now in its 6th year, Life Science Leader and Industry Standard Research (ISR) teamed up for the CRO Leadership Awards to provide readers with accurate and reliable customer feedback to assist them in choosing a reputable partner for their clinical research needs. Over 70 contract research organizations were assessed on 20+ performance metrics.

Survey participants were recruited from Pharma and Biopharma companies of all sizes and were screened for decision-making influence related to working with contract research organizations. Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months. This level of qualification ensures that survey responses are based on actual involvement with CROs and clear experiential data. Complete results will be published in the May edition of Life Science Leader magazine.

About Celerion 
Celerion, a global leader in early clinical research services, offers a unique combination of medical expertise, clinical operations experience and scientific excellence that gives our clients the confidence to make fast, accurate decisions about their drug development path. Our services include comprehensive clinical development services from Phase 1-2b, including patient dose response studies, cardiovascular safety and product labeling studies. In addition, Celerion offers statistics, data management and biostatistics, and bioanalytical services. Our founding mission is to help our clients get their drugs to market quickly, so that they touch the lives of our family, friends and people in need around the world.